Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia

Cited by (999)

Items 901–999 of 999

1. Long-Term Cardiovascular Disease Outcomes Following Bariatric Surgery
   Sneh Sonaiya, Alba Zevallos, Gina Lynn Adrales · 2024 · Journal of Surgical Research
2. The intervention of cannabinoid receptor in chronic and acute kidney disease animal models: a systematic review and meta-analysis
   Zihao Zhao, Qianqian Yan, Junwei Xie, Zhenjie Liu, Yong U. Liu, Yong Liu, Sijie Zhou, Shaokang Pan, Dongwei Liu, Jiayu Duan et al. · 2024 · Diabetology & Metabolic Syndrome
3. Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti‐obesity drugs
   Marjolein J. C. Willemen, Aukje Kaija Mantel-Teeuwisse, Sabine M. J. M. Straus, Hubert G. M. Leufkens, Toine C. G. Egberts, Miriam Sturkenboom · 2009 · Pharmacoepidemiology and Drug Safety
4. Significance of High HDL Cholesterol Levels in Japanese Men with Metabolic Syndrome
   Noboru Hiratsuka, Chizumi Yamada, Toshitake Mitsuhashi, Fumiyo Inabe, Nami Araida, Eiko Takahashi · 2011 · Internal Medicine
5. Cannabinoid Receptor Type 2 (CB2) Dependent and Independent Effects of WIN55,212-2 on Atherosclerosis in Ldlr-null Mice
   Douglas P. Thewke, Courtney Netherland-Van Dyke, Ward Rodgers, Makenzie L. Fulmer, Zachary Lahr · 2015 · Journal of Cardiology and Therapeutics
6. Cannabinoids and Effects on the Gastrointestinal Tract: A Focus on Motility
   Gema Vera, Jakub Fichna, Raquel Abalo · 2017 · Elsevier eBooks
7. Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research
   Ewa Galaj, Briana J. Hempel, Allamar R. Moore, Benjamin Klein, Guo‐Hua Bi, Eliot L. Gardner, Herbert H. Seltzman, Zheng‐Xiong Xi · 2022 · Translational Psychiatry
8. Why Multitarget Vasodilatory (Endo)cannabinoids Are Not Effective as Antihypertensive Compounds after Chronic Administration: Comparison of Their Effects on Systemic and Pulmonary Hypertension
   Patryk Remiszewski, Barbara Malinowska · 2022 · Pharmaceuticals
9. Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant
   Marie Maynadier, Ilaria Basile, Magali Gary‐Bobo · 2008 · Drug Discovery Today
10. Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data
    Kirk A. Bronander, Michael J. Bloch · 2007 · Vascular Health and Risk Management
11. The Endocannabinoid System as a Target for Obesity Treatment
    Louis J. Aronne, Uberto Pagotto, Gary D. Foster, Stephen N. Davis · 2008 · Clinical cornerstone
12. Current Management of Obesity in an Infertile Female-Recent Advances and Future Prospective Drugs
    Kulvinder Kochar Kaur, Gautam Allahbadia, Mandeep Singh · 2013 · Journal of Pharmacy and Nutrition Sciences
13. The endocannabinoid system as a novel approach for managing obesity.
    Joseph L Lillo · 2007 · PubMed
14. Non-Alcoholic Fatty Liver Disease
    Hui‐Hui Tan, Jason Pik‐Eu Chang · 2010 · Proceedings of Singapore Healthcare
15. Pharmacological Treatment of the Overweight Patient
    2007 · Humana Press eBooks
16. The Metabolic Syndrome and Cerebrovascular Disease: Suspicion and Evidence
    Antonio Gil-Núñez · 2007 · Cerebrovascular Diseases
17. Contemporary Startegies for Managing Cardiometabolic Risk Factors
    Stephen N. Davis · 2006 · Journal of Managed Care Pharmacy
18. MEDICAL MANAGEMENT OF OBESITY
    M. Giri · 2006 · Acta Clinica Belgica
19. Gut Peptide Agonism in the Treatment of Obesity and Diabetes
    Gerald Grandl, Aaron Novikoff, Richard D. DiMarchi, Matthias H. Tschöp, Timo D. Müller · 2019 · Comprehensive physiology
20. CB1 Ligand AM251 Induces Weight Loss and Fat Reduction in Addition to Increased Systemic Inflammation in Diet-Induced Obesity
    Lannie O’Keefe, Teresa Vu, Anna C Simcocks, Kayte A. Jenkin, Michael L. Mathai, Deanne Helena Hryciw, Dana S. Hutchinson, Andrew J. McAinch · 2022 · International Journal of Molecular Sciences
21. Cannabinoid receptor type 1 (CB1R) inhibits hypothalamic leptin signaling via β-arrestin1 in complex with TC-PTP and STAT3
    Gergő Szanda, Tony Jourdan, Éva Wisniewski, Reşat Çınar, Grzegorz Godlewski, Anikó Rajki, Jie Liu, Lee Chedester, Bence Szalai, András Dávid Tóth et al. · 2023 · iScience
22. The endocannabinoid system:A new approach to control cardiovascular disease
    Christopher Paul Cannon · 2005 · Clinical cornerstone
23. To Be or Not To Be—Obese
    Stuart R. Maudsley, Bronwen Martin, Josephine Mary Egan · 2011 · Endocrinology
24. The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease
    Bojan Z. Jorgačević, Danijela B. Vučević, Ivana D. Djuricic, Sladjana S. Sobajic, Dušan R. Mladenović, Milena N. Vesković, Rada Ješić-Vukićević, Tatjana S. Radosavljević · 2017 · Chemistry and Physics of Lipids
25. Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder
    Erin L. Martin, Aimee L. McRae‐Clark · 2020 · Current Addiction Reports
26. Metabolic and inflammatory functions of cannabinoid receptor type 1 are differentially modulated by adiponectin
    Qiong Wei, Jong Han Lee, Chia‐Shan Wu, Qun Sophia Zang, Shaodong Guo, Hui‐Chen Lu, Yuxiang Sun · 2021 · World Journal of Diabetes
27. CNR1 Genotype Influences HDL-Cholesterol Response to Change in Dietary Fat Intake
    Heidi J. Silver, Kevin Dean Niswender, Charles D. Keil, Lan Jiang, QiPing Feng, Sally Chiu, Ronald M. Krauss, Russell A. Wilke · 2012 · PLoS ONE
28. AM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitors
    Douglas P. Thewke, Natalie E. Freeman-Anderson, Theresa G. Pickle, Courtney Netherland-Van Dyke, Courtney Chilton · 2009 · Biochemical and Biophysical Research Communications
29. Rimonabant as a potential new treatment for an emerging epidemic of obesity-related glomerulopathy?
    Mohamed Hassan Ahmed · 2006 · Expert Opinion on Emerging Drugs
30. Endocannabinoids, CB1 Receptors, and Liver Disease: Hitting More Than One Bird With the Same Stone
    George Kunos, Bin Gao · 2008 · Gastroenterology
31. Fatty liver–based identification of two distinct hypertriglyceridemic subgroups in familial combined hyperlipidemia
    Martijn C.G.J. Brouwers, Marleen M. J. van Greevenbroek, Monique A. L. Bilderbeek-Beckers, Margee G. Robertus-Teunissen, Carla Kallen, Coen D.A. Stehouwer, Tjerk WA de Bruin · 2007 · Metabolism
32. Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin‐concentrating Hormone Receptor 1 Antagonist
    Peter Gennemark, Magnus Trägårdh, Daniel Lindén, Karolina Ploj, Anders Johansson, Andrew V. Turnbull, Björn Carlsson, Madeleine Antonsson · 2017 · CPT Pharmacometrics & Systems Pharmacology
33. Cannabis use and metabolic syndrome among clients with first episode psychosis
    Erik Stiles, Karl Christian Alcover, Bryan J. Stiles, Oladunni A. Oluwoye, Michael G. McDonell · 2020 · Early Intervention in Psychiatry
34. Clinical Investigations of Antiobesity Drugs
    John P.H. Wilding · 2007 · Elsevier eBooks
35. The Endocannabinoid System: Novel Pathway for Cardiometabolic Risk-Factor Reduction
    Stephen C. Woods · 2007 · JAAPA
36. The Endocannabinoid System in the Physiopathology of Metabolic Disorders
    Uberto Pagotto, Valentina Vicennati, Riccardo Pasquali · 2007 · Hormone Research in Paediatrics
37. Antihypertensive therapy in the obese hypertensive patient
    Marzena Chrostowska, Radosław Szczęch, Krzysztof Narkiewicz · 2006 · Current Opinion in Nephrology & Hypertension
38. The metabolic syndrome in China
    Bernard M.Y. Cheung · 2006 · British Journal of Clinical Pharmacology
39. Unravelling the complex dissociation of [3H]‐rimonabant from plated CB1 cannabinoid receptor‐expressing cells
    Marie Wennerberg, Anudharan Balendran, John C. Clapham, Georges Vauquelin · 2009 · Fundamental and Clinical Pharmacology
40. Is the metabolic syndrome a real clinical entity and should it receive drug treatment?
    Tamara Darsow, David M. Kendall, David G. Maggs · 2006 · Current Diabetes Reports
41. What Is the Potential Role of Cannabinoid-1 Receptor Blockade in Glucose and Lipid Management?
    Michael D. Jensen · 2007 · The American Journal of Medicine
42. Curcumin Reinforces MiR-29a Expression, Reducing Mesangial Fibrosis in a Model of Diabetic Fibrotic Kidney via Modulation of CB1R Signaling
    Yung‐Chien Hsu, Pey‐Jium Chang, Shih-Jiun Lin, Chia‐Ching Liaw, Ya‐Hsueh Shih, Lee-Wen Chen, Chun‐Liang Lin · 2021 · Processes
43. HDL2/HDL3 Ratio Changes, Metabolic Syndrome Markers, and Other Factors in a Japanese Population
    Kengo Moriyama, Eiko Takahashi · 2015 · Journal of Atherosclerosis and Thrombosis
44. Alterations in Clinical Characteristics of Blood Donors Post COVID-19 Recovery
    Fahad Al Ghamdi, Salma Naqvi, Fahad Ahmed Al-Abbasi, Sultan Alhayyani, Mirza Rafi Baig, Vikas Kumar, Firoz Anwar · 2022 · Current Pharmaceutical Design
45. Preclinical Developments in Antiobesity Drugs
    Steve P. Vickers, Sharon C. Cheetham · 2007 · Elsevier eBooks
46. Modulatory effects by CB1 receptors on rat spinal locomotor networks after sustained application of agonists or antagonists
    Priyadharishini Veeraraghavan, Andrea Nistri · 2015 · Neuroscience
47. Diabetes and Coronary Heart Disease
    Graham T. McMahon · 2011 · Springer eBooks
48. Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke
    Somnath Mukhopadhyay, David A. Tulis · 2007 · Cardiovascular & Hematological Agents in Medicinal Chemistry
49. Effects of Rimonabant, as Monotherapy and in Combination With Fenofibrate or Ezetimibe, on Plasma Adipokine Levels: A Pilot Study
    Matilda Florentin, Evangelos N. Liberopoulos, C. Tellis, Christos S. Derdemezis, Moses Elisaf, Alexandros D. Tselepis · 2009 · Angiology
50. Food energy efficiency, cannabinoids, and a slow death of the weight loss dogma
    Brent A. Neuschwander‐Tetri · 2007 · Hepatology
51. Does innovation in obesity drugs affect stock markets? An event study analysis
    Jorge V. Pérez–Rodríguez, Beatriz González López‐Valcárcel · 2012 · Gaceta Sanitaria
52. Pleiotropic effects of rimonabant and simvastatin on obesity associated multiple metabolic risk factors in rats.
    Neveen A. Salem, Naomi Assaf, Hanaa Hamdy Ahmed · 2012 · PubMed
53. Interactions of Cannabinoids With Biochemical Substrates
    Brian F. Thomas · 2017 · Substance Abuse Research and Treatment
54. Obesity-Associated Hypertension
    Gabriel Ikponmosa Uwaifo · 2012 · Humana Press eBooks
55. Differential sensitivity of chronic high-fat-diet-induced obesity in Sprague-Dawley rats
    Shakthi R.K. Devan, Surendar Arumugam, Ganesh Shankar, Suresh Poosala · 2018 · Journal of Basic and Clinical Physiology and Pharmacology
56. [Metabolic syndrome and live kidney donor: is this syndrome a contraindication to donation?].
    Domingo Hernández, Alejandra Alvarez, A.A. Pérez de Armas, Margarita Rufino, Esteban Porrini, Armando Torres · 2009 · PubMed
57. Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis
    Adam Fabisiak, Marcin Włodarczyk, Natalia Fabisiak, Martin Storr, Jakub Fichna · 2019 · Journal of Gastrointestinal and Liver Diseases
58. Abdominal adiposity: Early intervention and therapeutic options
    André Jacques Scheen · 2008 · Clinical cornerstone
59. The endocannabinoid-CB receptor system: a new player in the brain-gut-adipose field
    Ester Fride · 2006 · Biomedical Reviews
60. Molecular network of obesity: what does it promise for pharmacotherapy?
    Michael S. Myslobodsky · 2007 · Obesity Reviews
61. Effects of Combined Oleoyl-Estrone and Rimonabant on Overweight Rats
    Raquel Ferrer‐Lorente, Cristina Cabot, José–Antonio Fernández–Löpez, M. Alemany · 2007 · Journal of Pharmacological Sciences
62. Impact of Medical Therapy on Atheroma Volume Measured by Different Cardiovascular Imaging Modalities
    Mohamad Sinno, Mouaz Husayn Al-Mallah · 2010 · Cardiology Research and Practice
63. Controversies in Treating Diabetes
    Derek LeRoith, Aaron I. Vinik · 2008 · Humana Press eBooks
64. High-Density Lipoprotein Cholesterol
    Peter P. Toth and Antonio M. Gotto · 2013 · CRC Press eBooks
65. Non‐Alcoholic Fatty Liver Disease: A Pathophysiological Perspective
    Michael A. Fuchs, Arun Jayant Sanyal · 2009 · Wiley eBooks
66. Developmental programming of somatic growth, behavior and endocannabinoid metabolism by variation of early postnatal nutrition in a cross-fostering mouse model
    Felix Schreiner, Merle Ackermann, Michael Michalik, Eva Hucklenbruch‐Rother, András Bilkei‐Gorzó, Ildikó Rácz, Laura Bîndilă, Beat Lutz, Jörg Dötsch, Andreas David Zimmer et al. · 2017 · PLoS ONE
67. Is marijuana a foe of male sexuality? Data from a large cohort of men with sexual dysfunction
    Arcangelo Barbonetti, Giulia Rastrelli, Clotilde Sparano, Chiara Castellini, Linda Vignozzi, Mario Maggi, Giovanni Corona · 2023 · Andrology
68. Les antagonists du récepteur CB1 des cannabinoïdes : une nouvelle approche pour le traitement de la fibrose hépatique
    Fatima Teixeira-Clerc, Boris Julien, Pascale Grenard, Jeanne Tran Van Nhieu, Vanessa Deveaux, Liying Li, Valérie Serrière-Lanneau, Catherine A. Ledent, Ariane Mallat, Sophie Lotersztajn · 2006 · médecine/sciences
69. Effects of cranberry consumption on features of the metabolic syndrome: a systematic review and meta-analysis of randomized control trials
    Razie Hormoznejad, Anahita Mansoori, Seyed Ahmad Hosseini, Marzie Zilaee, Maryam Asadi, Mojdeh Fathi, Fateme Kiany · 2021 · Nutrition & Food Science
70. Cannabinoids and Myocardial Ischemia: Novel insights, Updated Mechanisms, and Implications for Myocardial Infarction
    Karim Seif El Dahan, Dima Machtoub, Gaelle P. Massoud, Suzanne Awni Nasser, Bassam N. Hamam, Firas H. Kobeissy, Fouad Anthony Zouein, Ali Hussein Eid · 2021 · Current Medicinal Chemistry
71. A Phase I Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety Profile of a Sublingually Administered Cannabidiol /Delta 9-tetrahydrocannabidiol (10: 1) Regimen in Diabetes Type 2 Patients
    Shima Afshar, Shayesteh Khalili, Gholamreza Amin, Mohammad Abbasinazari · 2023 · Iranian journal of pharmaceutical research
72. Endocannabinergic modulation of central serotonergic activity in healthy human volunteers
    Barbara Emons, Larissa Arning, Vera-Estelle Makulla, Maria-Theresia Suchy, Dimitrios Tsikas, Thomas Lücke, Jörg T. Epplen, Georg Juckel, Patrik Roser · 2023 · Annals of General Psychiatry
73. Treatment of low high-density lipoprotein cholesterol
    Zuhier Ahmed Awan, Khalid Al-Waili, Khalid Al‐Rasadi, Jacques J. Genest · 2008 · Canadian Journal of Cardiology
74. Mice Expressing a "Hyper-Sensitive" Form of the Cannabinoid Receptor 1 (CB1) Are Neither Obese Nor Diabetic
    David J. Marcus, Michael L. Zee, Brian J. Davis, Chris P. Haskins, Mary-Jeanette Andrews, Randa Amin, Angela N. Henderson, Ken Mackie, Traci A. Czyzyk, Daniel J. Morgan · 2016 · PLoS ONE
75. Endocannabinoids in Energy Homeostasis and Metabolic Disorders
    Isabel Matias, Vincenzo Di Marzo, Attila Köfalvi · 2007 · Springer eBooks
76. Childhood Obesity and Blood Pressure Regulation
    Albert P. Rocchini · 2010 · Humana Press eBooks
77. Rimonabant may induce atrial fibrillation
    Giuseppe Cocco, D. Chu · 2009 · BMJ
78. Current and novel therapies for the treatment of nonalcoholic steatohepatitis
    David van der Poorten, Jacob George · 2007 · Hepatology International
79. High‐Density Lipoprotein Cholesterol: A Potential Therapeutic Target for Prevention of Coronary Artery Disease
    Alexander Chernobelsky, M. Dominique Ashen, Roger Scott Blumenthal, Neil L. Coplan · 2007 · Preventive Cardiology
80. Review: Pharmacological approaches to reduce adiposity
    Caroline Day, Clifford J. Bailey · 2006 · The British Journal of Diabetes
81. Effects on Food Intake and Blood Lipids of Cannabinoid Receptor 1 Antagonist Treatment in Lean Rats
    Marianne Bennetzen, Maria P. Nielsen, Bjørn Richelsen, Steen B. Pedersen · 2008 · Obesity
82. Diaryl piperidines as CB1 receptor antagonists
    Jack D. Scott, Sarah W. Li, Hongwu Wang, Yan Xia, Charles L. Jayne, Michael W. Miller, Ruth A. Duffy, George C. Boykow, Timothy J. Kowalski, Brian D. Spar et al. · 2009 · Bioorganic & Medicinal Chemistry Letters
83. Modified scan protocol using multislice CT coronary angiography allows high quality acquisitions in obese patients: a case report
    Gastón A. Rodríguez-Granillo, Miguel A. Rosales, Elina Degrossi, Inés Durbano, Alfredo E. Rodríguez · 2006 · International journal of cardiac imaging
84. Genetic Forms of the Cardiometabolic Syndrome: What Can They Tell the Clinician?
    George Y. Yuan, Robert Alexander Hegele · 2007 · Journal of the CardioMetabolic Syndrome
85. Imaging of atherosclerotic plaques in obesity: excessive fat accumulation, plaque progression and vulnerability
    Yu Kataoka, Stephen James Nicholls · 2014 · Expert Review of Cardiovascular Therapy
86. Exenatide and rimonabant: New treatments that may be useful in the management of diabetes and obesity
    Jennifer B. Green, Mark N. Feinglos · 2007 · Current Diabetes Reports
87. Gastroenterology and Hepatology Clinical Research Update: 2005–2006
    Michael Camilleri · 2006 · Clinical Gastroenterology and Hepatology
88. Obesity: Which drug and when?
    Michael E. J. Lean, Adam Mullan · 2007 · International Journal of Clinical Practice
89. Update on Rimonabant—A Selective Cannabinoid CB1 Antagonist
    Steven T. Boyd, Brad Allen Fremming · 2006 · Annals of Pharmacotherapy
90. Cannabinoides endógenos en la enfermedad hepática: muchos dardos para una sola diana
    Vedrana Reichenbach, Josefa Ros, Wladimiro Jiménez · 2009 · Gastroenterología y Hepatología
91. Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice
    B. Chen, N. Hu · 2017 · Brazilian Journal of Medical and Biological Research
92. Synthesis and Pharmacological Characterization of Novel Peripheral Cannabinoid-1 Receptor Blockers Based on a Tricyclic Scaffold
    Asaad Gammal, Taher Nassar, Yael Soae, Noam Freeman, Amit Badihi, Saja Baraghithy, Alina Nemirovski, Joseph Tam, Simon Benita · 2025 · Journal of Medicinal Chemistry
93. Therapeutics in Metabolic Diseases
    Vijayakumar Natesan · 2022 · Advances in experimental medicine and biology
94. In(OTf) 3 -catalysed A 3 -annulation strategy towards the synthesis of pyrazole-tethered quinoline derivatives and assessment of their luminescent properties
    Rahul Jamra, Chandi C. Malakar, Sadhika Khullar, Virender Singh · 2024 · New Journal of Chemistry
95. Tratamiento farmacológico de la obesidad: presente, pasado y futuro
    Lisney Valdelamar, Moisés Rodríguez, Valmore Bermúdez, Elliuz Leal, Fernando Bermúdez, Mayela Cabrera, Edgardo Mengual, Carlos Silva, Anilsa Amell, Abdón Toledo · 2007 · Archivos Venezolanos de Farmacología y Terapéutica
96. Obesity and Diabetes
    Alexandra Kautzky‐Willer, Rosa Lemmens‐Gruber · 2012 · Handbook of experimental pharmacology
97. Induction of Glucose Intolerance by Acute Administration of Rimonabant
    Sanjay N. Mandhane, Prasanta Kumar Nayak, Durgesh Soni, Shakti Jain, John C. Ashton, Rajamannar Thennati · 2012 · Pharmacology
98. Antihyperlipidemic Activity of Rimonabant on High Cholesterol Diet Induced Hyperlipidemia in Rats
    Arshad Alioorani, Gaurav Dwivedi, Mayura A. Kale · 2011
99. The Obese Teen
    Laura D. Hoeman · 2007 · AJN American Journal of Nursing